REDWOOD CITY, Calif., June 14, 2021 /PRNewswire/ -- Nevro Corp. (NVRO) - Get Report, a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced it will host an analyst & investor briefing from the American Diabetes Association 81 st Scientific Sessions on Friday, June 25, 2021, beginning at 3:30 pm PT / 6:30 pm ET. Nevro Chairman, CEO and President D. Keith Grossman will host the event, which will include a clinical data update for the company's SENZA-PDN and SENZA-NSRBP clinical studies and a question & answer session. Nevro's Chief Medical Officer, David Caraway, MD, PhD, and Nevro's Chief Financial Officer, Rod MacLeod, will also participate in the event.
Investors interested in listening to the briefing may participate via conference call or webcast. The conference call can be accessed by dialing (833) 968-2321 in the U.S. or +1 7785602840 internationally, using Conference ID: 2819815. The live audio webcast can be accessed by clicking on the Investor Events link at https://nevro.com/English/us/investors/events-and-presentations/event-details/2021/Nevro-to-Host-Virtual-Investor-Briefing-from-ADA/default.aspx on June 25. This event is not part of the official ADA Scientific Sessions.
Internet Posting of Information
Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. Nevro's proprietary 10 kHz therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary 10 kHz therapy.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, HFX, the HFX logo, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp.
Investors and Media: Julie Dewey, IRCNevro Corp. Vice President, Investor Relations & Corp Communications650-433-3247 | email@example.com
View original content to download multimedia: http://www.prnewswire.com/news-releases/nevro-to-host-virtual-analyst--investor-briefing-301311170.html
SOURCE Nevro Corp.